Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Enterprise Value (2021 - 2025)

Krystal Biotech's Enterprise Value history spans 5 years, with the latest figure at -$827.8 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 38.54% year-over-year to -$827.8 million; the TTM value through Dec 2025 reached -$827.8 million, down 38.54%, while the annual FY2025 figure was -$827.8 million, 38.54% down from the prior year.
  • Enterprise Value for Q4 2025 was -$827.8 million at Krystal Biotech, down from -$731.1 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$343.1 million in Q3 2021 and bottomed at -$827.8 million in Q4 2025.
  • The 5-year median for Enterprise Value is -$504.8 million (2023), against an average of -$512.5 million.
  • The largest annual shift saw Enterprise Value rose 19.38% in 2023 before it tumbled 53.62% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$438.1 million in 2021, then grew by 13.45% to -$379.2 million in 2022, then plummeted by 40.35% to -$532.2 million in 2023, then fell by 12.28% to -$597.5 million in 2024, then plummeted by 38.54% to -$827.8 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Enterprise Value are -$827.8 million (Q4 2025), -$731.1 million (Q3 2025), and -$682.0 million (Q2 2025).